<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02305017</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-91067-125</org_study_id>
    <nct_id>NCT02305017</nct_id>
  </id_info>
  <brief_title>Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers</brief_title>
  <official_title>Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <authority>France: Committee for the Protection of Personnes</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-centre, open-label, randomised, two-way cross-over study consisting of 2 periods
      separated by a washout period of 14 days or more.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single-centre, open-label, randomised, two-way cross-over study consisting of 2 periods
      separated by a washout period of 14 days or more. In one period, subjects received three
      single-doses of 1 g paracetamol separated by 6 hours and 1.5 hours after the last
      paracetamol dose a single-dose of 50 mg OPC was administered.In the other period, a
      single-dose of 50 mg OPC was administered alone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cmax - Maximum Plasma Concentration</measure>
    <time_frame>before and ½, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hour post-OPC dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax - Maximum plasma concentration of opicapone on Day 12 following an oral single-dose of 50 mg OPC administered alone or 1.5 h after last 1 g Paracetamol administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax - Time of Occurrence of Cmax</measure>
    <time_frame>before and ½, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hour post-OPC dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tmax - time of occurrence of Cmax following an oral single-dose of 50 mg OPC administered alone or 1.5 h after last 1 g Paracetamol administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t - Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Last Sampling Time at Which the Drug Concentration Was at or Above the Lower Limit of Quantification</measure>
    <time_frame>before and ½, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hour post-OPC dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC0-t - area under the plasma concentration-time curve (AUC) from time zero to the last sampling time following an oral single-dose of 50 mg OPC administered alone or 1.5 h after last 1 g Paracetamol administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞ - Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity.</measure>
    <time_frame>before and ½, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hour post-OPC dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC0-∞ - AUC from time 0 to infinity following an oral single-dose of 50 mg OPC administered alone or 1.5 h after last 1 g Paracetamol administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Period 1 OPC + Paracetamol; Period 2 OPC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 BIA 9-1067 (Opicapone, OPC) + Paracetamol; Period 2 BIA 9-1067 (Opicapone, OPC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 1 OPC; Period 2 OPC+ Paracetamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 BIA 9-1067 (Opicapone, OPC) Period 2 BIA 9-1067 (Opicapone, OPC) + Paracetamol;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 9-1067</intervention_name>
    <description>BIA 9-1067 50 mg</description>
    <arm_group_label>Period 1 OPC + Paracetamol; Period 2 OPC</arm_group_label>
    <arm_group_label>Period 1 OPC; Period 2 OPC+ Paracetamol</arm_group_label>
    <other_name>OPC, Opicapone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>Paracetamol 1g</description>
    <arm_group_label>Period 1 OPC + Paracetamol; Period 2 OPC</arm_group_label>
    <arm_group_label>Period 1 OPC; Period 2 OPC+ Paracetamol</arm_group_label>
    <other_name>acetaminophen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who are able and willing to give written informed consent.

          -  Male or female subjects aged between 18 and 45 years, inclusive.

          -  Subjects of body mass index (BMI) between 19.0 and 30.0 kg/m2, inclusive.

          -  Subjects who are healthy as determined by pre-study medical history, physical
             examination, vital signs, complete neurological examination and 12-lead ECG.

          -  Subjects who have negative tests for HBsAg, anti-HCVAb and HIV-1 and HIV-2 Ab at
             screening.

          -  Subjects who have clinical laboratory test results clinically acceptable at screening
             and admission to each treatment period.

          -  Subjects who have a negative screen for alcohol and drugs of abuse at screening and
             admission to each treatment period.

          -  Subjects who are non-smokers or ex-smokers for at least 3 months.

          -  (If female) She is not of childbearing potential by reason of surgery or, if of
             childbearing potential, she uses an effective non-hormonal method of contraception
             (intrauterine device or intrauterine system; condom or occlusive cap [diaphragm or
             cervical or vault caps] with spermicidal foam or gel or film or cream or suppository;
             true abstinence; or vasectomized male partner, provided that he is the sole partner
             of that subject) for all the duration of the study.

          -  (If female) She has a negative serum pregnancy test at screening and a negative urine
             pregnancy test on Day -1 of each treatment period.

        Exclusion Criteria:

          -  Subjects who have a clinically relevant history or presence of respiratory,
             gastrointestinal, renal, hepatic, haematological, lymphatic, neurological,
             cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological,
             dermatological, endocrine, connective tissue diseases or disorders.

          -  Subjects who have a clinically relevant surgical history.

          -  Subjects who have any clinically relevant abnormality in the coagulation tests.

          -  Subjects who have any clinically relevant abnormality in the liver function tests (a
             case-by-case decision for any abnormality must be discussed with the Sponsor before
             inclusion).

          -  Subjects who have a history of relevant atopy or drug hypersensitivity, particularly
             to paracetamol or any COMT inhibitor.

          -  Subjects who have a history of alcoholism or drug abuse.

          -  Subjects who consume more than 14 units of alcohol a week.

          -  Subjects who have a significant infection or known inflammatory process at screening
             or admission to each treatment period.

          -  Subjects who have acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea,
             heartburn) at the time of screening or admission to each treatment period.

          -  Subjects who have received paracetamol within 2 weeks of admission to the first
             period.

          -  Subjects who have used any other medicines within 2 weeks of admission to first
             period that may affect the safety or other study assessments, in the investigator's
             opinion.

          -  Subjects who have previously received OPC.

          -  Subjects who have used any investigational drug or participated in any clinical trial
             within 90 days prior to screening.

          -  Subjects who have participated in more than 2 clinical trials within the 12 months
             prior to screening.

          -  Subjects who have donated or received any blood or blood products within the 3 months
             prior to screening.

          -  Subjects who are vegetarians, vegans or have medical dietary restrictions.

          -  Subjects who cannot communicate reliably with the investigator.

          -  Subjects who are unlikely to co-operate with the requirements of the study.

          -  Subjects who are unwilling or unable to give written informed consent.

          -  (If female) She is pregnant or breast-feeding.

          -  (If female) She is of childbearing potential and she does not use an approved
             effective contraceptive method or she uses oral contraceptives.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 16, 2015</lastchanged_date>
  <firstreceived_date>November 28, 2014</firstreceived_date>
  <firstreceived_results_date>July 22, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Period 1 OPC + Paracetamol; Period 2 OPC</title>
          <description>Period 1 BIA 9-1067 (Opicapone, OPC) + Paracetamol; Period 2 BIA 9-1067 (Opicapone, OPC)
BIA 9-1067: BIA 9-1067 50 mg
Paracetamol: Paracetamol 1g</description>
        </group>
        <group group_id="P2">
          <title>Period 1 OPC; Period 2 OPC+ Paracetamol</title>
          <description>Period 1 BIA 9-1067 (Opicapone, OPC) Period 2 BIA 9-1067 (Opicapone, OPC) + Paracetamol;
BIA 9-1067: BIA 9-1067 50 mg
Paracetamol: Paracetamol 1g</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Period 1 OPC + Paracetamol; Period 2 OPC</title>
          <description>Period 1 BIA 9-1067 (Opicapone, OPC) + Paracetamol; Period 2 BIA 9-1067 (Opicapone, OPC)
BIA 9-1067: BIA 9-1067 50 mg
Paracetamol: Paracetamol 1g</description>
        </group>
        <group group_id="B2">
          <title>Period 1 OPC; Period 2 OPC+ Paracetamol</title>
          <description>Period 1 BIA 9-1067 (Opicapone, OPC) Period 2 BIA 9-1067 (Opicapone, OPC) + Paracetamol;
BIA 9-1067: BIA 9-1067 50 mg
Paracetamol: Paracetamol 1g</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="28"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="28"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="14"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="14"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Maximum Plasma Concentration</title>
        <description>Cmax - Maximum plasma concentration of opicapone on Day 12 following an oral single-dose of 50 mg OPC administered alone or 1.5 h after last 1 g Paracetamol administration</description>
        <time_frame>before and ½, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hour post-OPC dose</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Opicapone Alone</title>
            <description>Opicapone, OPC, BIA 9-1079 alone</description>
          </group>
          <group group_id="O2">
            <title>Opicapone Plus Paracetamol</title>
            <description>Opicapone, OPC, BIA 9-1079 Paracetamol acetominophen</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cmax - Maximum Plasma Concentration</title>
            <description>Cmax - Maximum plasma concentration of opicapone on Day 12 following an oral single-dose of 50 mg OPC administered alone or 1.5 h after last 1 g Paracetamol administration</description>
            <units>ng/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="895" spread="375.9"/>
                  <measurement group_id="O2" value="986" spread="355"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax - Time of Occurrence of Cmax</title>
        <description>Tmax - time of occurrence of Cmax following an oral single-dose of 50 mg OPC administered alone or 1.5 h after last 1 g Paracetamol administration.</description>
        <time_frame>before and ½, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hour post-OPC dose</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Opicapone Alone</title>
            <description>Opicapone, OPC, BIA 9-1079</description>
          </group>
          <group group_id="O2">
            <title>Opicapone Plus Paracetamol</title>
            <description>Opicapone, OPC, BIA 9-1079 Paracetamol, acetominphen</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Tmax - Time of Occurrence of Cmax</title>
            <description>Tmax - time of occurrence of Cmax following an oral single-dose of 50 mg OPC administered alone or 1.5 h after last 1 g Paracetamol administration.</description>
            <units>hours</units>
            <param>Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-t - Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Last Sampling Time at Which the Drug Concentration Was at or Above the Lower Limit of Quantification</title>
        <description>AUC0-t - area under the plasma concentration-time curve (AUC) from time zero to the last sampling time following an oral single-dose of 50 mg OPC administered alone or 1.5 h after last 1 g Paracetamol administration</description>
        <time_frame>before and ½, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hour post-OPC dose</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Opicapone Alone</title>
            <description>Opicapone, OPC, BIA 9-1067 50 mg</description>
          </group>
          <group group_id="O2">
            <title>Opicapone Plus Paracetamol</title>
            <description>Opicapone, OPC, BIA 9-1067 50 mg Paracetamol, acetominophen, 1 g</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>AUC0-t - Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Last Sampling Time at Which the Drug Concentration Was at or Above the Lower Limit of Quantification</title>
            <description>AUC0-t - area under the plasma concentration-time curve (AUC) from time zero to the last sampling time following an oral single-dose of 50 mg OPC administered alone or 1.5 h after last 1 g Paracetamol administration</description>
            <units>ng.h/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2416" spread="884.3"/>
                  <measurement group_id="O2" value="2818" spread="1194"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-∞ - Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity.</title>
        <description>AUC0-∞ - AUC from time 0 to infinity following an oral single-dose of 50 mg OPC administered alone or 1.5 h after last 1 g Paracetamol administration.</description>
        <time_frame>before and ½, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 hour post-OPC dose</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Opicapone Alone</title>
            <description>Opicapone, OPC, BIA 9-1067 50 mg</description>
          </group>
          <group group_id="O2">
            <title>Opicapone Plus Paracetamol</title>
            <description>Opicapone, OPC, BIA 9-1067 50 mg Paracetamol, acetominophen, 1 g</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>AUC0-∞ - Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity.</title>
            <description>AUC0-∞ - AUC from time 0 to infinity following an oral single-dose of 50 mg OPC administered alone or 1.5 h after last 1 g Paracetamol administration.</description>
            <units>ng.h/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2451" spread="882"/>
                  <measurement group_id="O2" value="2850" spread="1188"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Opicapone Alone</title>
          <description>Opicapone, OPC, BIA 9-1079 alone</description>
        </group>
        <group group_id="E2">
          <title>Opicapone Plus Paracetamol</title>
          <description>Opicapone, OPC, BIA 9-1079 Paracetamol acetominophen</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA version 15.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research</name_or_title>
      <organization>Bial – Portela &amp; Cª, S.A.</organization>
      <phone>+351 229 866 100</phone>
      <email>jose.rocha@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
